Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients
Status:
Unknown status
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
In contrast to calcineurin inhibitors, sirolimus is known to exert remarkable
tolerance-promoting properties in multiple animal transplant models. Whether sirolimus is
capable of enhancing tolerance-related pathways and/or promoting complete withdrawal of
immunosuppressive drugs in human transplant recipients has not been previously addressed. The
goal of the investigators study is to evaluate the effects of sirolimus on previously
identified tolerogenic pathways in humans and, indirectly, to assess the capacity of this
drug to enhance the proportion of liver recipients undergoing successful immunosuppression
weaning.